Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles Expressing Toxoplasma gondii Rhoptry Protein 18
Open Access
- 22 September 2022
- Vol. 10 (10) , 1588
Abstract
Heterologous immunization is garnering attention as a promising strategy to improve vaccine efficacy. Vaccines based on recombinant baculovirus (rBV) and virus-like particle (VLP) are safe for use, but heterologous immunization studies incorporating these two vaccine platforms remain unreported to date. Oral immunization is the simplest, most convenient, and safest means for mass immunization. In the present study, mice were immunized with the Toxoplasma gondii rhoptry protein 18 (ROP18)-expressing rBVs (rBVs-ROP18) and VLPs (VLPs-ROP18) via oral, intranasal, and intramuscular (IM) routes to evaluate the protection elicited against the intracellular parasite T. gondii ME49 strain. Overall, boost immunization with VLPs-ROP18 induced a significant increase in T. gondii-specific antibody response in all three immunization routes. Parasite-specific mucosal and cerebral antibody responses were observed from all immunization groups, but the highest mucosal IgA response was detected from the intestines of orally immunized mice. Antibody-secreting cell (ASC), CD8+ T cell, and germinal center B cell responses were strikingly similar across all three immunization groups. Oral immunization significantly reduced pro-inflammatory cytokine IL-6 in the brains as well as that by IN and IM. Importantly, all of the immunized mice survived against lethal challenge infections where body weight loss was negligible from all three immunizations. These results demonstrated that protection induced against T. gondii by oral rBV-VLP immunization regimen is just as effective as IN or IM immunizations.Keywords
Funding Information
- National Research Foundation of Korea (2018R1A6A1A03025124, HV20C0085, HV20C0142)
- the Ministry of Health & Welfare, Republic of Korea (2018R1A6A1A03025124, HV20C0085, HV20C0142)
This publication has 36 references indexed in Scilit:
- Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1PLOS ONE, 2013
- Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategyVaccine, 2012
- The Rhoptry Proteins ROP18 and ROP5 Mediate Toxoplasma gondii Evasion of the Murine, But Not the Human, Interferon-Gamma ResponsePLOS Pathogens, 2012
- Effect of Needle Length When Immunizing Obese Adolescents With Hepatitis B VaccinePediatrics, 2010
- Cats andToxoplasma: Implications for Public HealthZoonoses and Public Health, 2010
- Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice modelVaccine, 2010
- Adverse events associated with intranasal influenza vaccine in the United StatesTherapeutic Advances in Respiratory Disease, 2008
- Prospective Assessment of the Effect of Needle Length and Injection Site on the Risk of Local Reactions to the Fifth Diphtheria-Tetanus-Acellular Pertussis VaccinationPediatrics, 2008
- NALT- versus PEYER'S-patch-mediated mucosal immunityNature Reviews Immunology, 2004
- Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro.Journal of Clinical Investigation, 1992